Steve Davis, Acadia Pharmaceuticals CEO
July 14, 2023 11:20 AM EDTUpdated 11:34 AM
Deals

Aca­dia gets more rights for Day­bue, fork­ing over $100M up­front af­ter an ‘im­pres­sive’ US launch

Tyler Patchen

News Reporter

Aca­dia Phar­ma­ceu­ti­cals is ac­quir­ing fur­ther rights to Neuren Phar­ma­ceu­ti­cals’ new­ly ap­proved Rett syn­drome treat­ment for $100 mil­lion amid a bet­ter-than-ex­pect­ed launch of the drug. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times